Zoetis (ZTS) Set to Post Earnings on Thursday

Key Points

• Zoetis is expected to report Q3 2026 results before market open on November 5. Analysts forecast earnings of $1.51 per share on $2.30 billion in revenue, while full-year guidance is set at $6.15–$6.25 EPS.
• In its prior quarter, Zoetis earned $1.87 per share, beating estimates by $0.02, though revenue of $2.47 billion fell short of expectations and declined 0.2% year over year.
• The stock recently traded near $77.67, well below its 52-week high of $146.11. Analysts’ consensus rating is Hold, with an average price target of $98.40, and the company announced a quarterly dividend of $0.53 per share.

Zoetis (NYSE:ZTS - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $1.51 per share and revenue of $2.30 billion for the quarter. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Investors may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the company earned $1.76 EPS. The firm's revenue for the quarter was down .2% compared to the same quarter last year. On average, analysts expect Zoetis to post $6.15 EPS for the current fiscal year and $6.31 EPS for the next fiscal year.

Zoetis Price Performance

Shares of Zoetis stock opened at $77.67 on Thursday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company has a market cap of $32.10 billion, a PE ratio of 12.80, a price-to-earnings-growth ratio of 1.20 and a beta of 0.74. The firm has a fifty day moving average price of $74.91 and a two-hundred day moving average price of $94.11. Zoetis has a fifty-two week low of $68.77 and a fifty-two week high of $146.11.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis's dividend payout ratio is presently 34.93%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ZTS shares. BNP Paribas Exane cut their target price on Zoetis from $146.00 to $110.00 and set an "outperform" rating for the company in a research report on Tuesday, August 11th. William Blair downgraded Zoetis from an "outperform" rating to a "market perform" rating in a research note on Thursday, August 6th. Morgan Stanley set a $85.00 target price on Zoetis in a report on Friday, August 7th. Barclays dropped their price target on Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 1st. Finally, Cantor Fitzgerald set a $94.00 price target on Zoetis in a report on Tuesday, August 25th. Seven research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of "Hold" and a consensus target price of $98.40.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company's product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.